NORTHWEST BIOTHERA COM USD0.001 (NWBO)

0.18
0.02 8.15
OTC
Prev Close 0.19
Open 0.20
Day Low/High 0.17 / 0.20
52 Wk Low/High 0.14 / 0.98
Volume 3.30M
Exchange OTC
Shares Outstanding 191.80B
Market Cap 32.41M
Div & Yield N.A. (N.A)

Latest News

Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K

Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K

Imagine a derailed freight train carrying dumpsters on fire. That's an accurate description of the Northwest Bio 10-K filed Monday night.

Northwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse

Northwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse

Northwest's inability to resolve the problems that froze the DCVax-L clinical trial -- and management's refusal to offer a public explanation for why it happened -- triggered the company's collapse.

Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash

Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash

Northwest Biotherapeutics, a regular visitor to the capital markets, has negotiated a note payment schedule with Whitebox Advisors.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

NW Bio Announces Phase II Clinical Trial Program Combining DCVax®-L And Pembrolizumab (Keytruda®) For Colorectal Cancer

NW Bio Announces Phase II Clinical Trial Program Combining DCVax®-L And Pembrolizumab (Keytruda®) For Colorectal Cancer

Trial to Be Led By University Of Mainz Center of Excellence

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data

Using Northwest Bio as an example, I'm going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don't want you to see.

NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference In London

NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference In London

Dr. Marnix Bosch, Chief Technical Officer, Presented

NASDAQ Accepts NW Bio Remediation Plan For Shares and Warrants Previously Issued to Cognate BioServices

NASDAQ Accepts NW Bio Remediation Plan For Shares and Warrants Previously Issued to Cognate BioServices

Shares and Warrants To Be Cancelled and Reduced; MFN To Be Removed from Contracts

Short of Cash, Northwest Bio Flirts With Insolvency

Short of Cash, Northwest Bio Flirts With Insolvency

The cancer immunotherapy company's cash position has plunged to the point where it may no longer be capable of paying its operating expenses.

NW Bio Enters First 180-Day Grace Period Relating To Non-Compliance With Nasdaq $1.00 Per Share Bid Requirement

NW Bio Enters First 180-Day Grace Period Relating To Non-Compliance With Nasdaq $1.00 Per Share Bid Requirement

Progress Also Reported On Additional Nasdaq Compliance Issue

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.

NW Bio Announces Scientific Advisory Board

NW Bio Announces Scientific Advisory Board

Leading Experts in Immunotherapies and Oncology From Both the US and Europe

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

NW Bio Announces Operations Updates

NW Bio Announces Operations Updates

New Developments Relating to Phase I and II Trials, Scientific Advisory Board and Nasdaq Compliance

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stocks.